Compare RDW & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | ANNX |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | N/A | 99 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 918.2M |
| IPO Year | N/A | 2020 |
| Metric | RDW | ANNX |
|---|---|---|
| Price | $10.21 | $6.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $12.67 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 23.0M | 2.8M |
| Earning Date | 03-09-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $296,147,000.00 | N/A |
| Revenue This Year | $11.62 | N/A |
| Revenue Next Year | $41.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.87 | $1.29 |
| 52 Week High | $26.66 | $6.83 |
| Indicator | RDW | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 71.30 |
| Support Level | $9.67 | $5.85 |
| Resistance Level | $12.46 | $6.83 |
| Average True Range (ATR) | 1.24 | 0.48 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 55.36 | 100.00 |
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.